DOSE INTENSIFICATION BY THE SIMULTANEOUS USE OF RHG-CSF AND ANTICANCER CHEMOTHERAPY

  • Authors:
    • AJ WEISS
    • RD LACKMAN
  • View Affiliations

  • Published online on: February 1, 1995     https://doi.org/10.3892/ijo.6.2.329
  • Pages: 329-332
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We have studied the simultaneous administration of rhG-CSF with doxorubicin, the latter given by continuous infusion either intra-arterially or intravenously, in a group of patients with various sarcomas. This has enabled us to substantially increase the dosage intensity of doxorubicin with a marked decrease in both hematologic and oral toxicity. While the data concerning anti-tumor activity is preliminary we believe that this combination has been responsible for a substantial increase in the effectiveness of doxorubicin in controlling the sarcomas. No adverse effect from combining doxorubicin given by infusion with rhG-CSF has been noted to date.

Related Articles

Journal Cover

February 1995
Volume 6 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
WEISS, A., & WEISS, A. (1995). DOSE INTENSIFICATION BY THE SIMULTANEOUS USE OF RHG-CSF AND ANTICANCER CHEMOTHERAPY. International Journal of Oncology, 6, 329-332. https://doi.org/10.3892/ijo.6.2.329
MLA
WEISS, A., LACKMAN, R."DOSE INTENSIFICATION BY THE SIMULTANEOUS USE OF RHG-CSF AND ANTICANCER CHEMOTHERAPY". International Journal of Oncology 6.2 (1995): 329-332.
Chicago
WEISS, A., LACKMAN, R."DOSE INTENSIFICATION BY THE SIMULTANEOUS USE OF RHG-CSF AND ANTICANCER CHEMOTHERAPY". International Journal of Oncology 6, no. 2 (1995): 329-332. https://doi.org/10.3892/ijo.6.2.329